- Home
- » Tags
- » Ixabepilone
Top View
- Preclinical Discovery of Ixabepilone, a Highly Active Antineoplastic Agent
- Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-Targeting Drugs Independent of Doubling Time
- Epothilones – Expanding the Options for Breast Cancer?
- Biomarker Analysis of Neoadjuvant Doxorubicin/ Cyclophosphamide Followed by Ixabepilone Or Paclitaxel in Early-Stage Breast Cancer
- Ixempra (Ixabepilone) AHM
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone HDJ2 As
- Chemotherapy Options for Metastatic HER2-Negative Breast Cancer After Prior Exposure to Anthracyclines and Taxanes
- Ixabepilone (Ixempra®) Office Administration
- Emetogenic Potential of Antineoplastic Agents
- Arsenic Trioxide Induces Depolymerization of Microtubules In
- Endometrial Carcinoma Treatment Regimens
- Ixabepilone Development Across the Breast Cancer Continuum: a Paradigm Shift
- An Epothilone B Analog, in Patients with Renal Cell
- For Health Professionals Who Care for Cancer Patients May 2009 Website Access At
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone DNAJA1
- Breast Cancer Breast Cancer Structure of the Breast
- Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012
- Ixabepilone Development Across the Breast Cancer Continuum: a Paradigm Shift
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- Survivorship Issues After Ch Th I Chemotherapy in Metastatic/Recurrent Endometrial Cancer
- Ixabepilone for Locally Advanced Or Metastatic Breast Cancer
- Ixabepilone (Interim Monograph)
- Full Text (PDF)
- Ixempra® (Ixabepilone) (Intravenous) -E- Document Number: MODA-0472 Last Review Date: 06/01/2021 Date of Origin: 07/01/2019 Dates Reviewed: 07/2019, 06/2020, 06/2021
- Hazardous Drug List
- IXEMPRA Safely and Effectively
- Synergistic Antitumor Activity of Ixabepilone (BMS-247550)Plus Bevacizumab in Multiple in Vivo Tu M O R Mo D E L S Francis Y.F
- SUMMARY REVIEW Office Director Review Page 1 of 6 NDA 201532 Halaven (Eribulin)
- A Phase I and Pharmacokinetic Study of Ixabepilone in Combination With
- Ixabepilone in Metastatic Breast Cancer: Complement Or Alternative to Taxanes? Antoinette R.Tan and Deborah L.Toppmeyer
- Prostate Cancer Chemotherapy in the Era of Targeted Therapy
- Optimizing Treatment in Metastatic Breast Cancer Ellen Kossoff, Pharmd, BCOP,1 Nuttapong Ngamphaiboon, MD,2 and Tracey L
- Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
- 5‑FU and Ixabepilone Modify the Microrna Expression Profiles in MDA‑MB‑453 Triple‑Negative Breast Cancer Cells